Patents Examined by Zohreh Fay
  • Patent number: 10351525
    Abstract: A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1, R3, Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R3, Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 16, 2019
    Assignee: Oxford University Innovation Limited
    Inventors: Jürgen Brem, Sander S. Van Berkel, Michael A. McDonough, Christopher J. Schofield
  • Patent number: 10350294
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10350161
    Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: July 16, 2019
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
  • Patent number: 10336779
    Abstract: Gold(I) complexes and gold(I) dithiocarbamate polymers as anticancer therapeutics. The Au(I) ion within the gold(I) complexes is coordinated to two phosphine ligands. The repeating unit formed by Au(I) ion coordinating to dithiocarbamate ligands are connected by Au(I)-Au(I) interactions within the gold(I) dithiocarbamate polymers. Also disclosed are methods of synthesis, pharmaceutical compositions incorporating the gold(I) complexes, pharmaceutical compositions incorporating the gold(I) dithiocarbamate polymers, and methods of treating cancer.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: July 2, 2019
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Anvarhusein A. Isab, Muhammad Altaf, Adam Ahmed Abdallah Seliman
  • Patent number: 10322112
    Abstract: Methods for modulating quorum sensing in certain Gram-negative bacteria having multiple QS systems including Las, Rhl, and Pqs with associated receptors (LasR, RhlR and PqsR) which are modulated by small molecule modulators, particularly non-native modulators. Certain combinations of modulators of Las, Rhl and Pqs exhibit improved inhibition of virulence in comparison to the respective individual modulators. In particular, certain combinations of modulators exhibit improved inhibition in nutritionally depleted environments. More specifically, certain combinations of modulators exhibit improved inhibition in environments depleted in phosphate and/or environments depleted in iron. Nutrient depleted environments can mimic environments associated with bacterial infection in humans and non-human animals. The methods are useful in particular for modulating QS in Pseudomonas and Burkholderia.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: June 18, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Helen Blackwell, Michael Welsh
  • Patent number: 10314927
    Abstract: The present invention relates to a method of preparation of formulations of gadolinium metal complexes of the macrocyclic chelator DOTA, which further comprise a small excess of free DOTA. The method uses controlled conditions such that excess gadolinium is present as a precipitate of gadolinium oxide, with filtration to remove the excess, prior to the addition of a defined excess of DOTA chelator. Also provided is a method of preparation of MRI contrast agents based on Gd-DOTA.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: June 11, 2019
    Assignee: GE HEALTHCARE AS
    Inventors: Mikkel Jacob Thaning, Andreas Richard Meijer
  • Patent number: 10307409
    Abstract: A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: June 4, 2019
    Assignee: Chase Pharmaceuticals Corporation
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • Patent number: 10307384
    Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 4, 2019
    Assignee: ZeaVision LLC
    Inventor: Dennis L. Gierhart
  • Patent number: 10308649
    Abstract: A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (AhR) ligand. The AhR ligand includes 11-Cl-BBQ, 10-Cl-BBQ, an analog of 11-Cl-BBQ, or combination thereof. The AhR ligand is administered topically, orally, transdermally, intravenously, subcutaneously, or with a nanoparticle. The AhR ligand induces regulatory T cells (AhR-Tregs). AhR-Treg cells block the differentiation of cytotoxic T-lymphocytes (CTL). The AhR ligand activates AhR in CD4+ T cells to induce CD4+ AhR-Tregs that suppress the development of effector CTL, thereby suppressing the development of CTL that attack host cells in graft versus host disease (GVHD) or ?-cells in the pancreas in diabetes mellitus type 1 (T1DM). The AhR ligand can also suppress development of CTL independently of Foxp3+ regulatory T cell induction. The AhR ligand can therefore be used to treat autoimmune diseases characterized by an absence of functional Foxp3+ regulatory T cell.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 4, 2019
    Assignee: Oregon State University
    Inventors: Nancy I. Kerkvliet, Siva Kumar Kolluri
  • Patent number: 10294204
    Abstract: Provided is a fluorescent compound represented by the following [Chemical Formula 1] and a method for preparing the same: wherein each of X, Y, R1, R2, R3 and n is the same as defined in the specification.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: May 21, 2019
    Assignee: BIOACTS CO., LTD.
    Inventors: Jin Woo Park, Su-Jung Jang, Kiwon Kim, Gyeong Rim Shin, Bongkyu Lee
  • Patent number: 10285995
    Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: May 14, 2019
    Assignee: Topokine Therapeutics, Inc.
    Inventors: Cynthia L. Grosskreutz, Louis R. Pasquale, Michael S. Singer, Murat V. Kalayoglu
  • Patent number: 10286076
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: May 14, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10272015
    Abstract: Methods to enable a visual check on the mixing proper pharmaceutical compounding kits. The methods include providing a kit with a colored inactive to be added to the mixture. When the mixture is uniform or resembles a predetermined color, the mixture is assumed to be properly mixed.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 30, 2019
    Inventors: Austin Bonderer, Clark Levi
  • Patent number: 10266549
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: April 23, 2019
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • Patent number: 10251896
    Abstract: This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 9, 2019
    Assignee: Amylyx Pharmaceuticals Inc.
    Inventors: Joshua Cohen, Justin Klee
  • Patent number: 10244760
    Abstract: The present invention relates to an ophthalmic solution comprising 0.00001 to 10.0 weight percent of a simple saccharide, at least 0.00001 weight percent of a preservative, and not more than about 0.2 percent by weight chloride. The simple saccharide is chosen from the group consisting of: inositol; mannitol; sorbitol; sucrose; dextrose; glycerin; propylene glycol; ribose; triose; tetrose; erythrose; threose; pentose; arabinose; ribulose; xylose; xylulose; lyxose; hexose; allose; altrose; fructose; galactose; glucose; gulose; idose; mannose; sorbose; talose; tagatose; adlose; ketose; heptose; sedoheptulose; monosaccharides; disaccharides; sugar alcohols; xylitol; and polyol.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 2, 2019
    Assignee: FXS VENTURES, LLC
    Inventor: Francis X. Smith
  • Patent number: 10238635
    Abstract: There is provided a composition for treating a neuroinflammatory disease comprising a N-carbamoylated urethane compound which has an effect of inhibiting the activity of microglia or astrocytes and the production of nitric oxide (NO) and TNF-?, and suppressing the expression of IL-1? And iNOS genes. There is also provide a method for treating a neuroinflammatory disease, the method comprising the step of administering a N-carbamoylated urethane compound. Due to its above mentioned effects, the N-carbamoylated urethane compound according to the present invention can be useful for the treatment of neuroinflammatory diseases.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: March 26, 2019
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Kyoungho Suk, Gyun Jee Song, Youngpyo Nam, Myungjin Jo
  • Patent number: 10238616
    Abstract: An immunomodulator useful for modulating immune function and maintaining intravital homeostasis is provided. The immunomodulator comprises S-1-propenycysteine or a salt thereof as an active ingredient.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: March 26, 2019
    Assignee: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Junichiro Suzuki, Yukihiro Kodera, Kenji Itoh, Toshiaki Matsutomo
  • Patent number: 10227308
    Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: March 12, 2019
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRCIH, UNIVERSITÄT ZÜRICH
    Inventors: Simon M. Ametamey, Juergen Fingerle, Luca Gobbi, Uwe Grether, Ahmed Haider, Thomas Hartung, Linjing Mu, Leo Nicholls, Mark Rogers-Evans, Christoph Ullmer
  • Patent number: 10226420
    Abstract: A method comprising administering an effective amount of a topical dipyridamole to a subject in need thereof due to conjunctivitis.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: March 12, 2019
    Assignee: O.D. OCULAR DISCOVERY LTD
    Inventor: Moshe Rogosnitzky